These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35140195)

  • 1. A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban.
    Wang ZY; Wan YD; Liu XZ; Wang H; Jiang GY; Yang B
    Med Sci Monit; 2022 Feb; 28():e934341. PubMed ID: 35140195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population.
    Kingdon LK; Miller EM; Savage SA
    J Surg Res; 2019 Dec; 244():509-515. PubMed ID: 31336243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
    Anderson DR; Dunbar M; Murnaghan J; Kahn SR; Gross P; Forsythe M; Pelet S; Fisher W; Belzile E; Dolan S; Crowther M; Bohm E; MacDonald SJ; Gofton W; Kim P; Zukor D; Pleasance S; Andreou P; Doucette S; Theriault C; Abianui A; Carrier M; Kovacs MJ; Rodger MA; Coyle D; Wells PS; Vendittoli PA
    N Engl J Med; 2018 Feb; 378(8):699-707. PubMed ID: 29466159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
    Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
    Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
    Khorana AA; Soff GA; Kakkar AK; Vadhan-Raj S; Riess H; Wun T; Streiff MB; Garcia DA; Liebman HA; Belani CP; O'Reilly EM; Patel JN; Yimer HA; Wildgoose P; Burton P; Vijapurkar U; Kaul S; Eikelboom J; McBane R; Bauer KA; Kuderer NM; Lyman GH;
    N Engl J Med; 2019 Feb; 380(8):720-728. PubMed ID: 30786186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study.
    Camporese G; Bernardi E; Noventa F; Bosco M; Monteleone G; Santoro L; Bortoluzzi C; Freguja S; Nardin M; Marullo M; Zanon G; Mazzola C; Damiani G; Maniscalco P; Imberti D; Lodigiani C; Becattini C; Tonello C; Agnelli G;
    Thromb Haemost; 2016 Aug; 116(2):349-55. PubMed ID: 27075710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of extended prolonged venous thromboembolism prophylaxis with rivaroxaban after major abdominal and pelvic surgery - overview of safety and early outcomes.
    Tyselskyi V; Wong D; Tryliskyy Y; Poylin V; Kebkalo A
    Pol Przegl Chir; 2020 Sep; 92(6):22-27. PubMed ID: 33408260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
    Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
    N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban for Thromboprophylaxis After Nonelective Orthopedic Trauma Surgery in Switzerland.
    Hoffmeyer P; Simmen H; Jakob M; Sommer C; Platz A; Ilchmann T; Grossen E; Ryf C; Christofilopoulos P; Schueler M; Lassen MR; Rimle M; Gasser UE
    Orthopedics; 2017 Mar; 40(2):109-116. PubMed ID: 27874908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
    Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
    Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
    Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study.
    Yhim HY; Lee J; Lee JY; Lee JO; Bang SM
    PLoS One; 2017; 12(5):e0178214. PubMed ID: 28542415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled trial on the efficacy of tranexamic acid combined with rivaroxaban thromboprophylaxis in reducing blood loss after primary cementless total hip arthroplasty.
    Clavé A; Gérard R; Lacroix J; Baynat C; Danguy des Déserts M; Gatineau F; Mottier D
    Bone Joint J; 2019 Feb; 101-B(2):207-212. PubMed ID: 30700116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
    Spyropoulos AC; Lipardi C; Xu J; Lu W; Suh E; Yuan Z; Levitan B; Sugarmann C; De Sanctis Y; Spiro TE; Barnathan ES; Raskob GE
    Clin Appl Thromb Hemost; 2019; 25():1076029619886022. PubMed ID: 31746218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis.
    Liu J; Zhao J; Yan Y; Su J
    Medicine (Baltimore); 2019 Mar; 98(9):e14539. PubMed ID: 30817570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
    N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
    Wells PS; Prins MH; Levitan B; Beyer-Westendorf J; Brighton TA; Bounameaux H; Cohen AT; Davidson BL; Prandoni P; Raskob GE; Yuan Z; Katz EG; Gebel M; Lensing AWA
    Chest; 2016 Nov; 150(5):1059-1068. PubMed ID: 27262225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
    Wang Y; Wang M; Ni Y; Liang Z
    Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.